增加借款却不能带来业务利润的增长。近几年来，国恩股份收入虽有增长，但净利润徘徊不前，包括公 司实控人在内的一众高管，并没有因为国恩股份利润徘徊而放弃加薪。与此同时，公司员工的人均收入 却不增反降。 2025年6月底递交港股上市招股书后，9月初国恩股份（002768）收到证监会反馈意见，就公司股本变 化、实控人债务和控制权以及业务经营等问题提出问询。 国恩股份不只存在实控人偿债能力问题，近些年来，国恩股份的资产负债率一年高比一年，有息债务不 断增长。尤其是短期债务方面，公司短期债务的增长尤为明显，由之而来的利息费用不断膨胀。 利润徘徊短债攀升 国恩股份已经在A股上市，此次港股上市成功后，公司将成为实现"A+H"两地上市公司中新的一员。 国恩股份横跨化工和健康两大领域，化工是公司核心收入来源。公司以有机高分子材料改性业务为基 石，向上游延伸至苯乙烯、聚苯乙烯、可发性聚苯乙烯及聚丙烯等绿色石化材料业务。 公司援引弗若斯特沙利文资料，按2024年中国高分子材料改性相关板块营收计算，国恩股份是中国第二 大的有机高分子材料改性生产企业。按2024年中国聚苯乙烯相关产能计，公司是中国最大的聚苯乙烯生 产企业。 2022年， ...

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 10 companies, including Guoen Technology, regarding their overseas listing application [1] - Guoen Technology submitted its listing application to the Hong Kong Stock Exchange on June 26, 2025, with CMB International as the sole sponsor [1] - The CSRC has requested Guoen Technology to clarify the debt repayment capability of its actual controller and whether its projects are classified as "high energy consumption" or "high emissions" [1] Group 2 - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency [3] - The company implements a "one body, two wings" development strategy, establishing a vertically integrated industrial platform in the large chemical and health industries [3] - In the large chemical sector, Guoen Technology focuses on the chemical new materials industry chain, building a "new materials+" ecological circle and extending upstream to green petrochemical materials [3] - In the health sector, Guoen Technology concentrates on the natural collagen industry, developing a vertically integrated product layout from animal collagen to end products [3]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 10 companies, including Guoen Technology, regarding their overseas listing applications [1] - Guoen Technology submitted its listing application to the Hong Kong Stock Exchange on June 26, 2025, with CMB International as its sole sponsor [1] - The CSRC has requested Guoen Technology to clarify the debt repayment ability of its actual controller and whether its projects are classified as "high energy consumption" or "high emissions" [1] Group 2 - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency [3] - The company implements a "one body, two wings" development strategy, establishing a vertically integrated industrial platform in the large chemical and health industries [3] - In the large chemical sector, Guoen Technology is involved in the chemical new materials industry chain, creating a "new materials+" industrial ecosystem [3] - The company extends its operations upstream to green petrochemical materials and deepens its downstream layout in various industries, including electronics, automotive, new energy, and energy storage [3] - In the health sector, Guoen Technology focuses on the natural collagen industry, developing a vertically integrated product layout from animal collagen to end products [3]

Core Viewpoint - Guoen Co., Ltd. is striving for an IPO on the Hong Kong Stock Exchange to expand its global production capacity and address financial pressures due to rising debt levels and declining profit margins [1][2][8]. Group 1: Company Overview - Guoen Co., Ltd. is a leading player in the domestic chemical new materials industry, focusing on two main sectors: large chemicals and health [1]. - The company has a diverse product range, including collagen, hollow capsules, gelatin, and organic polymer materials, which are essential raw materials for pharmaceuticals, health products, home appliances, food, and some industrial products [1]. - Founded in 2000 by Wang Aiguo, Guoen has grown from a startup to a major industry leader, with annual revenues nearing 20 billion RMB [3][4]. Group 2: Financial Performance - The company's revenue increased from 750 million RMB in 2015 to 19.19 billion RMB in 2024, while net profit rose from 72.24 million RMB to 685 million RMB during the same period [6]. - However, the asset-liability ratio has surged from 28.36% in 2015 to 61.68% in 2024, with total liabilities increasing from 280 million RMB to 11.32 billion RMB, indicating a significant reliance on debt for expansion [8][9]. - As of the end of 2024, the company had cash and cash equivalents of 2.015 billion RMB, insufficient to cover short-term borrowings of 2.217 billion RMB, highlighting liquidity challenges [9][10]. Group 3: Market Challenges - Guoen's gross profit margin has been declining, from 14.75% in 2021 to 8.71% in 2024, which constrains profitability [15]. - The large chemicals segment faces intense competition and price wars, while the health segment is impacted by procurement pressures from downstream pharmaceutical companies [16]. - In Q1 2025, the company reported a revenue decline of 0.23% year-on-year, marking the first drop in nearly a decade, with net profit decreasing by 9.8% [16]. Group 4: Strategic Initiatives - The company plans to use the funds raised from the Hong Kong IPO to enhance its global production capacity, including establishing production bases in Thailand, Vietnam, and Mexico [2][19]. - Guoen aims to increase its overseas revenue share, which was only 1.58% in 2024, as part of its strategy to mitigate growth bottlenecks [19]. - The international expansion is seen as a necessary step to align with the global market demands and improve cost efficiency [19].

Core Viewpoint - Qingdao Guoen Technology Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its capital market strategy and aiming to enhance its international influence and competitiveness [1] Group 1: Company Overview - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency and implementing a "one body, two wings" development strategy in the large chemical and health industries [2] - In the large chemical sector, Guoen Technology is the second-largest organic polymer material modification producer in China and the largest producer of polystyrene, showcasing its strong market position [2] - In the health industry, Guoen Technology's subsidiary Dongbao Biological has established a comprehensive product layout from collagen to "collagen +", becoming a significant player in the health sector [3] Group 2: Financial Performance - The company has shown strong revenue growth, with total revenues of approximately RMB 134.06 billion, RMB 174.39 billion, and RMB 191.88 billion for the fiscal years 2022, 2023, and 2024, respectively [4] - The main revenue source is the large chemical sector, contributing RMB 183.3 billion in 2024, accounting for 95.6% of total revenue, while the health sector contributed RMB 8.53 billion, representing 4.4% of total revenue [5] - The overall gross profit margins for the fiscal years 2022, 2023, and 2024 were 11.8%, 9.2%, and 8.3%, respectively, with the health sector showing a higher margin of 23.2% in 2024 [6] Group 3: Future Prospects - The successful listing on the Hong Kong Stock Exchange is expected to provide new development opportunities for the company, allowing it to expand capacity, increase R&D investment, and enhance its domestic and international market presence [6] - The company's strong foundation in the large chemical and health sectors, along with its financial performance and future growth potential, positions it as a noteworthy investment opportunity [7]